Supplemental Figure 1. (A) Soluble fractalkine levels are attenuated with ADAM10 inhibition following co-stimulation with TNFα and IFNγ. Astrocytes (grown in standard media) were pre-treated with the ADAM10 inhibitor (GI 254023X; 1µM), for 30 min. Cells were then co-stimulated with TNFα (1ng/ml) and IFNγ (1ng/ml) for 18 hr. Quantification of CX3CL1 ELISA revealed a significant decrease in soluble fractalkine when pre-treated with ADAM10 inhibitor. ###p<0.001 compared to own control and ***p<0.001 compared to matched treated group (One way ANOVA and Tukey’s post-hoc test). Values expressed as averages +/- SEM; n=4, duplicates. (B,C) Changes in levels of sCX3CL1 is not associated with cell death. Astrocytes were treated with (B) IL-1β (100pg/ml), TNFα (10ng/ml) and IFNγ (10ng/ml) or (C) a pan MMP inhibitor (MMP inhib.) Marimastat (1µM), specific ADAM10 inhibitor (GI 254023X; 1µM) and the p38 inhibitor, VX-702 (1µM) all for 18 hrs. Cell viability was analysed using MTT assay. A significant increase in cell viability is seen with IL-1β and TNFα. **P<0.01 and ***P<0.001; One way ANOVA and Tukey’s post hoc test. Values expressed as averages +/- SEM; n=5, triplicates. (D) Cytokines do not increase protein levels of the active form of ADAM10. Astrocytes were treated with IL-1β (100pg/ml), TNFα (10ng/ml) and IFNγ (10ng/ml) for 18 hrs before western blotting (representative of 3 independent experiments). In all cases, human astrocytes were serum starved for 3 hr before treatments.